February 20, 2024


You are Your Only Limit

PDS Biotechnology Announces Conference Contact and Webcast for 2nd Quarter 2023 Financial Effects

2 min read

PDS Biotechnology Company

PRINCETON, N.J., Aug. 07, 2023 (World NEWSWIRE) — PDS Biotechnology Company (Nasdaq: PDSB), a medical-phase immunotherapy firm producing a increasing pipeline of specific cancer immunotherapies and infectious sickness vaccines centered on the Company’s proprietary T mobile activating platforms, these days declared that the Business will launch fiscal effects for the 2nd quarter of 2023 on Monday, August 14, 2023, in advance of the market opens. Next the release, administration will host a conference simply call to evaluation the fiscal outcomes and deliver a enterprise update.

Monday, August 14, 2023, 8:00 AM ET 
Domestic: 877-407-3088
International: 201-389-0927
Convention ID: 13739270 
Webcast: PDS Biotech Earnings Webcast

After the reside webcast, the celebration will be archived on PDS Biotech’s site for six months.

About PDS Biotechnology 
PDS Biotech is a medical-stage immunotherapy organization building a growing pipeline of specific most cancers and infectious condition immunotherapies based on our proprietary Versamune®, Versamune® moreover PDS0301, and Infectimune® T mobile-activating platforms. We think our focused immunotherapies have the opportunity to overcome the limitations of present-day immunotherapy techniques as a result of the activation of the appropriate style, amount and efficiency of T cells. To date, our direct Versamune® scientific applicant, PDS0101, has shown the capacity to minimize and shrink tumors and stabilize sickness in combination with accepted and investigational therapeutics in people with a wide vary of HPV16-associated cancers in several Phase 2 clinical trials and will be advancing into a Phase 3 medical demo in mixture with KEYTRUDA® for the remedy of recurrent/metastatic HPV16-favourable head and neck cancer in 2023. Our Infectimune® based mostly vaccines have also demonstrated the potential to induce not only robust and sturdy neutralizing antibody responses, but also effective T cell responses, which includes prolonged-long lasting memory T mobile responses in pre-clinical experiments to day. To understand extra, you should take a look at www.pdsbiotech.com or comply with us on Twitter at @PDSBiotech.

Trader Contacts:
Deanne Randolph
PDS Biotech
Cellular phone: +1 (908) 517-3613
E-mail: [email protected]

Rich Cockrell
CG Money
Phone: +1 (404) 736-3838
E mail: [email protected]

Media Contacts: 
Tiberend Strategic Advisors, Inc.
Dave Schemelia 
Cell phone: +1 (609) 468-9325 
[email protected]

Eric Reiss
Phone: +1 (802) 249-1136
[email protected]

bionpa.com All rights reserved. | Newsphere by AF themes.